DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

Kashiv Biosciences, LLC

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
24/09/2025
Mercado laboral
Industria
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
11/09/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Mercado laboral
Industria
Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
05/08/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab)
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
25/06/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Industria
Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab)
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
07/04/2025
Mercado laboral
Salud
Ciencia
Farmacéutica
Biotecnología
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
26/03/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
25/02/2025
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Industria
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
28/01/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Industria
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
10/12/2024
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
01/11/2024
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0